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Oncogenic transcription factors drive many human cancers, yet identifying and therapeutically targeting the 
resulting deregulated pathways has proven difficult. Squamous cell carcinoma (SCC) is a common and lethal 
human cancer, and relatively little progress has been made in improving outcomes for SCC due to a poor under-
standing of its underlying molecular pathogenesis. While SCCs typically lack somatic oncogene-activating 
mutations, they exhibit frequent overexpression of the p53-related transcription factor p63. We developed an 
in vivo murine tumor model to investigate the function and key transcriptional programs of p63 in SCC. Here, 
we show that established SCCs are exquisitely dependent on p63, as acute genetic ablation of p63 in advanced, 
invasive SCC induced rapid and dramatic apoptosis and tumor regression. In vivo genome-wide gene expression 
analysis identified a tumor-survival program involving p63-regulated FGFR2 signaling that was activated by 
ligand emanating from abundant tumor-associated stroma. Correspondingly, we demonstrate the therapeutic 
efficacy of extinguishing this signaling axis in endogenous SCCs using the clinical FGFR2 inhibitor AZD4547. 
Collectively, these results reveal an unanticipated role for p63-driven paracrine FGFR2 signaling as an addicting 
pathway in human cancer and suggest a new approach for the treatment of SCC.
Introduction
Squamous cell carcinoma (SCC) is a treatment-refractory malig-
nancy arising within the epithelium of the skin, lung, esopha-
gus, and upper aerodigestive tract (so-called head and neck SCC, 
HNSCC). SCC is largely a carcinogen-induced tumor, as major 
risk factors include tobacco, alcohol, and sun exposure. Little 
progress has been made in improving overall survival from SCC 
during the past 30 years, in part because of a limited understand-
ing of the molecular pathobiology of this disease (1). SCCs do not 
commonly harbor somatic oncogene-activating mutations, but 
instead are associated with frequent mutational inactivation of 
tumor suppressor pathways including p53 and NOTCH, the thera-
peutic implications of which remain to be established (2, 3). In 
addition, although the EGFR is an attractive therapeutic target 
that is overexpressed or amplified in a subset of cases, only lim-
ited success with EGFR-directed therapy has been achieved in SCC 
despite intensive efforts over many years (4, 5). Recent systematic 
sequencing studies of HNSCC have confirmed the remarkable 
rarity of tumor-associated somatic mutations in well-established 
oncogenic drivers, which include HRAS (4% of cases) and the PI3K 
catalytic subunit PIK3CA (7% of cases) (2, 3). Thus, new approach-
es are needed to identify the key biological drivers in SCC in order 
to develop more effective and selective therapies for this disease.
One underexplored area for potential therapeutic intervention 
in SCC and other cancers involves deregulation of various lineage-
specific transcription factors (6). The p53-related transcription 
factor p63 (TP63), a master regulator of embryonic epithelial devel-
opment, is subject to overexpression and/or genomic amplifica-
tion in up to 80% of primary HNSCC tumors as well as in SCCs 
of the skin, lung, and esophagus (7, 8). Numerous p63-regulated 
transcriptional target genes and programs have been identified 
through developmental and cell-culture studies, including differ-
entiation, adhesion signaling, and senescence suppression (9–11). 
While several of these genes and pathways could in theory con-
tribute to tumorigenesis, it is unknown which if any are relevant 
in the context of p63-expressing tumors in vivo. Indeed, the pre-
cise role of p63 in cancer may be context dependent, as loss rather 
than overexpression of p63 is associated with disease progression 
in some tumors, including bladder cancer (12). These seemingly 
paradoxical results could be in part attributable to distinct func-
tions of different p63 protein variants. The p63 locus is expressed 
as multiple isoforms, most notably through 2 promoters that pro-
duce N-terminal variants either containing or lacking the p53-like 
transactivation domain (TAp63 or ΔNp63, respectively) (13). Data 
from mouse models indeed support isoform-specific functions 
of p63 in both development and cancer. While germline inactiva-
tion of p63 (14) or ΔNp63 (15) results in mice lacking skin and 
limbs and is perinatal lethal, selective TAp63 deficiency produces 
viable animals that exhibit an increase in metastatic tumors (16). 
Notably, the major p63 isoform expressed in stratified squamous 
epithelium and SCC is ΔNp63α (17, 18).
The interactions between tumor cells and their microenviron-
ment likely play an essential role in SCC pathogenesis, providing 
another fertile area for investigation and potential therapeutic 
intervention. Substantial data point to essential and possibly dis-
tinct roles for immune cells and stromal cells in SCC initiation 
and progression (19, 20). Of particular interest in recent years has 
been the contribution of tumor-associated fibroblasts. In many 
cancers, these cells have been shown to contribute to tumor pro-
liferation, differentiation, and invasion as well as creation of a 
permissive environment for tumor formation and maintenance 
(20). Encasement of tumor cells within a dense fibrous stroma 
is a hallmark of HNSCC and other squamous tumors, and high 
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2013;123(8):3525–3538. doi:10.1172/JCI68899.
Downloaded from http://www.jci.org on December 26, 2014.   http://dx.doi.org/10.1172/JCI68899
research article
3526 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 8   August 2013
levels of stromal infiltrate are associated with a poor prognosis 
in these malignancies (21, 22). Despite the clinical and biological 
importance of tumor stroma in SCC, however, previous work has 
provided few therapeutically actionable insights and the precise 
mechanisms of this stromal contribution are poorly understood.
Given the potentially complex role of p63 in SCC, understand-
ing its precise contribution to cancer pathogenesis in the autoch-
thonous tumor context could provide major new insights into this 
disease. We therefore established an endogenous SCC model to 
test the effect of deleting all p63 isoforms within established, inva-
sive tumors. This experiment demonstrated exquisite dependence 
of SCC on high levels of p63. Extensive in vivo analysis revealed a 
deregulated paracrine FGFR2 signaling program that is controlled 
directly by p63, activated by stroma-derived ligand, and required 
for tumor survival. We then validated these findings and their 
therapeutic relevance using a clinical FGFR2 inhibitor to induce 
apoptosis of advanced endogenous tumors.
Results
Development and validation of a robust murine SCC model. SCC is a 
cancer caused by prolonged, repeated carcinogen exposure. There-
fore, to generate a murine SCC model that would recapitulate 
the features of the human disease we employed a well-established 
protocol of weekly carcinogen (7,12-dimethyl-benz[a]anthracene 
[DMBA]) treatment in the oral cavity (23) or on the back (24–26). 
These SCCs were readily distinguishable from nonmalignant pap-
illomas in both appearance and size (Figure 1, A and B). Tumors 
were locally invasive and exhibited metastases to lymph nodes and 
lung in a subset of cases (∼13%), (Figure 1B). These tumors shared 
the histologic features of human SCC, including variable degrees 
of ongoing squamous epithelial differentiation and high levels of 
nuclear p63 expression (Figure 1B). Similar to human SCC, these 
tumors also expressed robust levels of EGFR and cyclin D1 pro-
teins (Supplemental Figure 1A; supplemental material available 
online with this article; doi:10.1172/JCI68899DS1), and resemble 
the recently described “classical SCC” that develops in carcinogen-
treated mice (27). Human SCCs frequently harbor inactivating 
mutations in p53 (2, 3, 28), and p53 inactivation is important 
for SCC progression in genetic models of oral SCC, cooperat-
ing potently with events such as AKT activation (29). Consistent 
with these data, we found that SCC tumors arising in DMBA-
treated p53+/– mice appeared at reduced latency compared with 
those occurring in WT mice (Figure 1C) (30, 31). These tumors 
showed evidence of p53 loss or mutation as do human SCC pri-
mary tumors and cell lines (Supplemental Figure 1). Like human 
SCCs, our murine tumors express higher levels of p63 mRNA 
and protein than normal skin, corresponding to the ΔNp63α 
isoform (Figure 1, D and E, and refs. 10, 18, 32). Using FACS of 
disaggregated tumors to isolate cells expressing the epithelial-
specific α6-integrin (CD49f) (33), we observed levels of ΔNp63 
Figure 1
Murine SCC tumors share molecular features of human SCC. (A) Kaplan-Meier curve of progression of histologically defined papillomas com-
pared with SCC tumors. Tumors were considered progressive when they passed 100 mm3 size threshold. (B) Primary and metastatic SCC tumors 
from DMBA-treated mice share the histologic features (H&E) — note stromal elements (arrows) and differentiated keratin “pearls” (arrowheads) — 
and nuclear p63 expression (IHC) of human SCC. Scale bars: 25 μm. (C) Haploinsufficiency for p53 reduces tumor latency following weekly 
DMBA treatment. p53+/+, n = 25, p53+/–, n = 61. P value assessed by log-rank test. (D) Increased expression of p63 mRNA in DMBA-induced SCCs 
versus normal skin. mRNA levels were assessed by QRT-PCR and normalized to β-actin. Error bars represent SEM. (E) Predominant expression 
of ΔNp63α protein (arrowhead) in murine SCC tumors. Whole-tumor lysates were assessed for p63 expression using an antibody that detects all 
isoforms. GAPDH serves as a loading control. (F) ΔNp63 is overexpressed relative to TAp63 in murine SCC tumors. Whole tumors were disag-
gregated and sorted for CD49fhi (α-6 integrin) epithelial cells, and mRNA levels were assessed as in D.
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Figure 2
p63 is required for maintenance of autochthonous SCC tumors in vivo. (A) IHC of K14 and p63 in SCC tumors. Scale bars: 25 μm. (B) PCR 
analysis of DNA from tissues of a p63L/L K14-CreER mouse treated with daily i.p. injection of 100 mg/kg tamoxifen for 5 consecutive days. The 
p63Brdm3 allele generated after excision and primer locations are shown in Supplemental Figure 2A. (C) IHC of p63 protein expression in tumors 
of indicated genotypes 72 hours after treatment with vehicle or tamoxifen as above. Scale bars: 25 μm. (D) Volume of cutaneous tumors in p63+/L 
(n = 4), p63L/L (n = 6), p63+/L K14-CreER (n = 3), or p63L/L K14-CreER (n = 6) mice following tamoxifen treatment (arrows). Tumor volume was 
normalized to size 1 day prior to treatment. P < 0.0001 for p63L/L K14-CreER compared with each control group as assessed by multiple measures 
ANOVA. (E) Representative histology (H&E) and IHC staining for Ki67 and cleaved caspase 3 (CC3) of tumors from tamoxifen-treated p63L/L or 
p63L/L K14-CreER mice. Scale bar: 25 μm. (F) Quantification of cleaved caspase 3 staining in control versus tamoxifen-treated p63L/L K14-CreER 
tumors, shown as percentage of field staining positive. *P < 0.05 as determined by Mann-Whitney test. (G) Quantification of Ki67-positive cells in 
control versus tamoxifen-treated K14-CreER tumors. *P < 0.05; **P < 0.01 as determined by Student’s unpaired t test. Error bars represent SEM. 
See Methods for details of controls in F and G.
Downloaded from http://www.jci.org on December 26, 2014.   http://dx.doi.org/10.1172/JCI68899
research article
3528 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 8   August 2013
mRNA between 50- and 200-fold greater than TAp63 (Figure 1F), 
consistent with similar findings observed in human HNSCC cell 
lines (18). Taken together, these data demonstrate that this model 
shares key molecular and histologic features of human SCC.
Exquisite sensitivity of autochthonous SCC to loss of p63. To determine 
whether tumors were dependent on p63, we employed a condi-
tional p63 allele (p63L/L) (Supplemental Figure 2A). A previous 
study showed that Cre-mediated recombination in homozygous 
p63L/L mice during embryogenesis recapitulates both the genomic 
structure and the phenotype of the p63-null mouse (34). In order 
to control p63 excision in a tissue- and temporal-specific man-
ner, we crossed these mice to a transgenic strain expressing the 
Cre recombinase/estrogen receptor (CreER) fusion protein from 
the keratin 14 (K14) promoter (35). Notably, our murine tumors 
demonstrate high overlap between p63 and K14 expression 
(Figure 2A), as was previously shown in human SCC (36). Given 
the importance of p53 in human SCC, we then performed addi-
tional crosses to generate p63L/L K14-CreER mice on a p53+/– back-
ground for DMBA treatment. Mice were administered DMBA on 
the back skin or in the oral cavity until tumors reached approxi-
mately 100 mm3, a size not reached by papillomas (Figure 1A), 
then treated for 5 consecutive days with 100 mg/kg tamoxifen. 
Allele-specific PCR (Supplemental Figure 2A) demonstrated that 
p63 was excised only in tissues that normally express K14 (Figure 2B 
and ref. 37). Immunohistochemical (IHC) staining 72 hours 
after tamoxifen treatment confirmed that p63 is rapidly and 
efficiently ablated from established SCC tumors in a temporally 
controlled manner (Figure 2C).
A tumor-bearing cohort of p63L/L K14-CreER mice served as 
the experimental arm, while tumor-bearing cohorts of p63L/L, 
p63+/L, and p63+/L K14-CreER mice served as controls. All tumors 
of control mice showed progressive growth following tamoxifen 
Figure 3
Comprehensive analysis of p63-reg-
ulated transcription in SCC in vivo. 
(A) Schematic of orthotopic tumor 
generation for microarray analysis. 
Representative histology (H&E) 
and p63 IHC staining of a primary 
tumor and its derivative orthotopic 
tumor are shown. Scale bars: 25 μm. 
(B) Overlap between p63-regu-
lated genes identified in murine 
SCC tumors and previously identi-
fied p63-regulated genes in cul-
tured MK (81). P value for overlap 
assessed by hypergeometric test. 
(C) Heat map of integrin signaling, 
FGF signaling, and RAS/MAPK 
signaling genes identified by 
DAVID analysis (39) as differen-
tially expressed between p63-
intact and p63-ablated tumors. 
The p63L/L K14-CreER consists of 
vehicle-treated p63-ablated (n = 3), 
and p63-ablated group consists of 
tamoxifen-treated p63L/L K14-CreER 
(n = 3). Hatch marks indicate genes 
shared by all 3 pathways.
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treatment (Figure 2D). In contrast, all p63L/L K14-CreER tumors 
showed rapid and dramatic regression within a few days of p63 
excision, which was observed in both cutaneous (Figure 2D and 
Supplemental Figure 2B) and oral SCCs (Supplemental Fig-
ure 2C). Importantly, we saw no evidence of effects on normal 
epithelial tissues, consistent with the reported effects of p63 
loss in the normal epidermis that appear only after a period of 
months (34). Histological analysis after the last dose of tamoxi-
fen demonstrated apoptotic features in p63L/L K14-CreER tumors 
compared with control p63L/L tumors (Figure 2E). Staining for 
cleaved caspase 3 by IHC confirmed the marked induction of 
apoptosis in these tumors (Figure 2, E and F). In addition, Ki67 
staining demonstrated a significant decrease in proliferation in 
the tamoxifen-treated p63L/L K14-CreER tumors compared with 
controls, which became more pronounced at later time points 
after excision (Figure 2, E and G). Taken together, these data 
demonstrate exquisite dependence of endogenous SCC on p63 
for survival and proliferation.
A central role for p63-regulated developmental signaling in endogenous 
SCC. It is unknown whether any of the established transcriptional 
targets or functions of p63 are critical for maintenance of SCC 
in vivo. In order to systematically identify such key programs, we 
performed global gene expression 
profiling following p63 genomic 
excision using an orthotopic pri-
mary tumor transplant system we 
developed (Figure 3A and ref. 25). 
Importantly these tumors can be 
serially transplanted (Supplemen-
tal Figure 3A) and grow with rapid 
kinetics (Supplemental Figure 3, 
B and C). This system therefore 
allows us to generate multiple 
tumors with the same genetic 
alterations and endogenous 
tumor stroma, all growing in vivo 
at the same time and at the same 
rate in multiple mice. We can thus 
conduct carefully controlled rep-
licate in vivo experiments. Nota-
bly, these tumors share the same 
histological features and p63 
expression as the primary tumor 
(Figure 3A). Similar to autoch-
thonous tumors (Figure 2D), 
only p63L/L K14-CreER tumors and 
not p63L/L tumors had reduced 
growth following tamoxifen treat-
ment (Supplemental Figure 3, B 
and C). We then collected whole 
tumors at multiple defined inter-
vals following treatment, prepared 
RNA, and performed global gene 
expression profiling using Illumi-
na MouseWG-6 BeadChip arrays. 
Results were analyzed for signifi-
cant differences between p63L/L 
K14-CreER tumors treated with 
vehicle (hereafter p63-intact) and 
tamoxifen (hereafter p63-ablated), 
revealing 834 transcripts that had a greater than 1.5-fold change 
and a P value of less than 0.05 following p63 excision.
The physiologic relevance of this p63-ablated versus p63-intact 
gene expression data set is supported by the significant overlap 
we observed between genes changed following p63 excision in our 
SCC tumors (Figure 3B) and those regulated in normal murine 
keratinocytes (MK) following p63-directed siRNA (38). We then 
used the Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) (39) tool to carry out pathway analysis on these 
genes. Indeed, Gene Ontogeny (GO) analysis revealed “epithelium 
development” and “epithelial cell differentiation” as 2 of the most 
significant GO terms for both SCC and MK gene sets and for 
the set of overlapping genes (Table 1). This finding suggests that 
deregulation of its normal developmental programs may contrib-
ute to p63-dependent tumor maintenance. Consistent with this 
possibility, pathway analysis identified genes involved in integrin 
signaling (e.g., Col6α2, Col17α1, Lamβ3), an important p63-regu-
lated developmental program (9, 15, 40), as enriched following p63 
excision in SCC (Table 1 and Figure 3C). This analysis also uncov-
ered a functional signature associated with Ras/MAPK signaling, 
involving genes including Dusp6, Egr1, and Etv4, and Pld1 (Table 1 
and Figure 3C). Notably, this transcriptional program has not 
Table 1
p63-regulated pathways in murine SCC assessed by DAVID
Category Term Count P value
KEGG_PATHWAY mmu05200:Pathways in cancer 23 7.36 × 10–4
KEGG_PATHWAY mmu05212:Pancreatic cancer 8 8.60 × 10–3
KEGG_PATHWAY mmu04810:Regulation of actin cytoskeleton 14 2.43 × 10–2
KEGG_PATHWAY mmu04010:MAPK signaling pathway 16 2.55 × 10–2
KEGG_PATHWAY mmu04340:Hedgehog signaling pathway 6 3.03 × 10–2
KEGG_PATHWAY mmu04144:Endocytosis 13 3.16 × 10–2
KEGG_PATHWAY mmu04370:VEGF signaling pathway 7 3.67 × 10–2
KEGG_PATHWAY mmu04670:Leukocyte transendothelial migration 9 3.97 × 10–2
KEGG_PATHWAY mmu04666:Fc gamma R-mediated phagocytosis 8 4.00 × 10–2
KEGG_PATHWAY mmu04960:Aldosterone-regulated sodium reabsorption 5 4.67 × 10–2
KEGG_PATHWAY mmu05219:Bladder cancer 5 4.67 × 10–2
PANTHER_PATHWAY P04393:Ras Pathway 10 4.87 × 10–3
PANTHER_PATHWAY P00034:Integrin signaling pathway 17 9.26 × 10–3
PANTHER_PATHWAY P00021:FGF signaling pathway 11 2.15 × 10–2
GOTERM_BP_FAT GO:0060429∼epithelium development 25 5.07 × 10–6
GOTERM_BP_FAT GO:0048732∼gland development 20 1.50 × 10–5
GOTERM_BP_FAT GO:0030879∼mammary gland development 13 1.52 × 10–5
GOTERM_BP_FAT GO:0035239∼tube morphogenesis 18 2.84 × 10–5
GOTERM_BP_FAT GO:0035295∼tube development 22 9.37 × 10–5
GOTERM_BP_FAT GO:0030855∼epithelial cell differentiation 14 1.32 × 10–4
GOTERM_BP_FAT GO:0048729∼tissue morphogenesis 20 1.93 × 10–4
GOTERM_BP_FAT GO:0022612∼gland morphogenesis 11 2.98 × 10–4
GOTERM_MF_FAT GO:0003779∼actin binding 22 4.02 × 10–4
GOTERM_BP_FAT GO:0060443∼mammary gland morphogenesis 7 5.07 × 10–4
GOTERM_BP_FAT GO:0008544∼epidermis development 13 5.79 × 10–4
GOTERM_BP_FAT GO:0001763∼morphogenesis of a branching structure 13 5.79 × 10–4
GOTERM_MF_FAT GO:0005198∼structural molecule activity 29 6.42 × 10–4
GOTERM_BP_FAT GO:0030036∼actin cytoskeleton organization 15 7.29 × 10–4
GOTERM_BP_FAT GO:0060562∼epithelial tube morphogenesis 12 7.44 × 10–4
GOTERM_CC_FAT GO:0005886∼plasma membrane 122 8.55 × 10–4
GOTERM_BP_FAT GO:0001666∼response to hypoxia 9 8.57 × 10–4
GOTERM_MF_FAT GO:0008092∼cytoskeletal protein binding 27 8.69 × 10–4
GOTERM_BP_FAT GO:0070482∼response to oxygen levels 9 9.50 × 10–4
GOTERM_BP_FAT GO:0007398∼ectoderm development 13 1.01 × 10–3
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Figure 4
Direct regulation and requirement for p63-induced Fgfr2 in SCC. (A) QRT-PCR assessment of mRNA levels of indicated genes in p63-intact (n = 3–5) 
or p63-excised (n = 3–4) orthotopic tumor samples normalized to β-actin. (B) Western blot of indicated proteins in SCC tumors of indicated genotype. 
Ribosomal S6 serves as a loading control. T, tamoxifen. (C) ChIP of endogenous p63 at the Col17α1, Pld1, and Fgfr2 loci in murine B9 SCC cells 
using indicated antibodies. Control designates highly conserved region –2.4 kb upstream of Fgfr2 promoter. (D) ChIP of exogenously expressed, 
FLAG-epitope tagged WT ΔNp63α or DNA-binding–deficient ΔNp63α (R304W) in B9 cells. GFP-expressing cells serve as a negative control. 
(E) Relative Fgfr mRNA levels in autochthonous murine tumors, normalized to β-actin. (F) Correlation between ΔNp63 and FGFR2 mRNA levels in 
human primary HNSCC tumors as assessed by TaqMan QRT-PCR. P value was calculated using Pearson product-moment correlation coefficient. 
(G) Human FaDU HNSCC cells plated in soft agar 72 hours after infection with p63 or FGFR2-directed shRNAs. (H) Western blot analysis of FaDU 
HNSCC cells stably expressing indicated proteins 72 hours following infection with p63-directed shRNA or control shRNA. Exogenous ΔNp63α 
(WT) and ΔNp63α (R304W) contain a FLAG epitope tag and are resistant to p63 shRNA (47). GAPDH serves as a loading control. (I) Colony form-
ing assay of samples in H 10 days after infection with p63-directed or control shRNA. *P < 0.05; **P < 0.01; ***P < 0.001 as assessed by Student’s 
unpaired t test for all experiments except where indicated. Error bars represent SEM.
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been previously ascribed to p63, but may contribute to p63 func-
tion in SCC, given that each of these genes has functional links to 
RAS/MAPK pathway activation in cancer (41, 42).
A third p63-dependent transcriptional program emerging from 
this analysis involved genes associated with FGF signaling, includ-
ing Fgfr2 and Fgfr3 (Table 1 and Figure 3C). FGF signaling seemed 
to be a particularly noteworthy and potentially important pathway 
controlled by p63 in SCC for several reasons. First, this signaling 
pathway and these factors in particular are likely to be relevant in 
p63-expressing cells, as Fgfr2 IIIb–/– mice bear striking similarities 
to p63–/– mice, including dramatic failure of limb and skin devel-
opment (14, 43). Indeed, both FGFR2 and FGFR3 expression have 
been linked to p63 in a developmental context (40, 44). Second, 
we discovered through analysis of public data sets that FGFR2 is 
highly significantly overexpressed together with p63 in human 
SCC tumors versus normal epithelia (Supplemental Figure 3, D 
and E). Third, although neither FGFR2 nor FGFR3 has previously 
been associated with p63 in human cancer, both genes encode 
bona fide oncogenes and are subject to activating somatic altera-
tions in human tumors (45, 46). Finally, there is significant overlap 
among all 3 of the p63-regulated gene sets we identified (integrin 
signaling, RAS/MAPK activation, FGF signaling), suggesting that 
these programs may converge on a common program that is essen-
tial for tumor maintenance (Figure 3C).
Direct p63-mediated regulation and requirement for FGFR2 signaling in 
SCC. We next validated the microarray results, using quantitative 
RT-PCR (QRT-PCR) to confirm reduced mRNA levels of Fgfr2/3, 
the adhesion- and RAS/MAPK-associated genes in p63-ablated 
tumors compared with p63-intact tumors (Figure 4A). In contrast, 
we saw no significant changes in control genes, including Fgfr1, 
Fgfr4, or Egfr, following inactivation of p63 (Figure 4A). Reduction 
in Col17α1, Pld1, Fgfr2, and Fgfr3 mRNA was further confirmed 
in primary autochthonous murine SCC tumors (Supplemen-
tal Figure 4A), and reduction of the corresponding proteins was 
confirmed by Western analysis (Figure 4B). We then wished to 
determine whether the p63-regulated genes were subject to direct 
transcriptional control by p63 in SCC, since neither Col17α1 nor 
Pld1 had previously been identified as p63-regulated genes. We 
performed ChIP using α-p63 antibodies in murine B9 SCC cells 
(Supplemental Figure 4B) and observed significant p63 binding 
upstream of the Col17α1 and Fgfr2 transcription start sites and in 
the first intron of Pld1 (Figure 4C). To confirm the specificity of 
these findings, we expressed FLAG-epitope–tagged WT ΔNp63α 
(WT) or a DNA-binding deficient point mutant ΔNp63α (R304W) 
(47) in B9 cells and performed ChIP using antibodies against the 
FLAG epitope (Supplemental Figure 4B). Only cells expressing WT 
ΔNp63α demonstrated significant binding of ΔNp63α to the Pld1 
and Fgfr2 loci (Figure 4D). Collectively, these data identify Col17α1, 
Pld1, and Fgfr2 as direct, p63-activated target genes in SCC.
The Fgfr2 transcript undergoes alternative splicing, resulting in 
an Fgfr2 IIIb isoform, preferentially expressed on epithelial cells, 
and an Fgfr2 IIIc isoform expressed on mesenchymal cells (48). 
Examination of mRNA levels in autochthonous SCC tumors 
(Figure 4E) showed that the epithelial-specific Fgfr2 IIIb isoform 
was expressed at substantially higher levels than Fgfr2 IIIc or 
Fgfr3, suggesting that Fgfr2 IIIb is the most relevant p63-regulat-
ed isoform in SCC. In order to establish the relevance of FGFR2 
in human tumors, we first examined the regulation of FGFR2 
by p63 in HNSCC cell lines. As was seen in murine tumors, 
lentiviral-mediated knockdown of p63 resulted in substantially 
reduced FGFR2 levels in human HNSCC cells (Supplemental Fig-
ure 4C). Next, we obtained primary human HNSCC tumor sam-
ples and examined the relationship between ΔNp63 and FGFR2 
expression. Using QRT-PCR we found that FGFR2 and ΔNp63 
mRNA levels were directly and highly statistically significantly 
correlated in these tumors (Figure 4F), consistent with a direct 
regulatory relationship.
We then wished to test the functional contribution of the p63-FGFR2 
axis in SCC. Significantly, we found that lentiviral knockdown of 
either p63 or FGFR2 in human HNSCC cells was associated with 
similar dramatic suppression of anchorage-independent growth 
(Figure 4G) and colony forming ability (Supplemental Figure 4D). 
To determine whether p63 is sufficient to induce FGFR2 expres-
sion in this setting, we expressed either a WT ΔNp63α isoform, the 
DNA-binding–deficient mutant ΔNp63α (R304W), or TAp63α 
(WT) in HaCAT-immortalized human keratinocytes. Only WT 
ΔNp63α induced significant expression of FGFR2 (Supplemental 
Figure 4E), suggesting that ΔNp63α alone can activate FGFR2. To 
directly test the requirement for FGFR2 signaling in p63-depen-
dent tumor maintenance, we performed a genetic rescue experi-
ment in human FaDU HNSCC cells. We stably expressed either a 
control GFP protein or an shRNA-resistant FLAG-epitope tagged 
ΔNp63α (WT) or ΔNp63α (R304W) (47), followed by lentiviral-
mediated knockdown of endogenous p63 (Figure 4H). Expression 
of ΔNp63α (WT) was able to significantly rescue the decreased soft 
agar colony formation following p63 knockdown, while the DNA-
binding–deficient ΔNp63α (R304W) was not (Figure 4I). Most 
remarkably, overexpression of the IIIb isoform of FGFR2, but not 
the IIIc isoform, was able to rescue colony formation to the same 
extent as ΔNp63α itself (Figure 4I). Collectively, these data sug-
gest that FGFR2 IIIb is a key activated target of p63 in SCC, and 
they demonstrate the essential role of p63-dependent FGFR2 IIIb 
signaling in both human and murine SCC.
A paracrine FGF7-FGFR2 signaling axis is upregulated in autochthonous 
tumors. We noted substantially increased expression of both p63 and 
its target FGFR2 in murine (Figure 5A) and human (Supplemental 
Figure 5A) autochthonous tumors relative to multiple SCC cell lines, 
leading us to hypothesize that the p63-dependent FGFR2 signaling 
axis might be more highly activated in tumors as compared with 
cultured cells. Indeed, immunofluorescent (IF) staining of primary 
tumors, using K14 as an epithelial cell marker and vimentin as a 
stromal marker, demonstrated dramatic membrane FGFR2 stain-
ing and nuclear p63 staining selectively within malignant epithelial 
cells (Figure 5B). The ligands for the epithelial-expressed FGFR2 IIIb 
include FGF1 and FGF7 and are typically produced by mesenchymal 
cells during normal development, resulting in paracrine signaling 
(49, 50). Consistent with the hypothesis that stromal-derived ligands 
signal in a paracrine fashion to FGFR2 IIIb in autochthonous SCC, 
IF showed that tumor cells were surrounded by a dense vimentin-
positive stroma (Figure 5B). The tumor stroma appeared to comprise 
activated fibroblasts, as evidenced by SMA staining (Supplemental 
Figure 5B). Furthermore, we documented highly elevated expres-
sion of multiple FGFR2 ligands, including FGF1, FGF7, and FGF10 
in whole tumors compared with cultured cell lines, with FGF1 and 
FGF7 being the most highly expressed (Figure 5C and Supplemental 
Figure 5C). We then examined expression of Fgf7, the most specific 
of the ligands for FGFR2 IIIb, and p63 in FACS-isolated cell popula-
tions from autochthonous tumors, comparing CD49f (α6-integrin) 
positive (tumor) versus negative (stromal) cells following exclusion of 
hematopoietic and endothelial cells. We observed robust expression 
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Figure 5
Deregulation of a paracrine FGFR2 signaling axis in autochthonous SCC. (A) Upregulation of p63 (left) and FGFR2 (right) in SCC tumors 
versus cell lines. Relative mRNA expression was determined by QRT-PCR in murine SCC cell lines (n = 5) and tumors (n = 5). Bar indicates 
mean value. *P < 0.05 as assessed by Student’s unpaired t test. (B) IF staining of autochthonous murine SCC tumors, showing colocalization 
of K14, nuclear p63, and membrane-associated FGFR2. Vimentin (green) identifies stromal cells. Hoechst dye (blue) identifies nuclei. Scale 
bars: 25 μm. (C) Upregulation of FGFR2 ligands in SCC tumors. Relative mRNA expression of Fgf7 (left) and Fgf1 (right) in murine SCC cell 
lines (n = 5) and tumors (n = 5). Bars indicate mean value. *P < 0.05 as assessed by Student’s unpaired t test. (D) Stroma-specific expression 
of FGF7 in autochthonous SCC. Primary tumors were disaggregated, then separated by FACS into epithelial CD49fhi (α-6 integrin) and stromal 
(CD49flo) populations following elimination of hematopoietic (CD45+) and endothelial (CD31+) cells prior to RNA analysis. Note epithelial-specific 
expression of p63. Error bars indicate SEM.  **P < 0.01, ***P < 0.001. (E) Spatially restricted FGF7 engagement in normal epithelia is abolished 
in SCC. IF staining of murine hair follicle in telogen (top) and autochthonous murine SCC tumors (bottom) for FGF7. K14 staining identifies 
epithelial cells. Note highly restricted expression in hair follicle (arrow) compared with tumor. HS, hair shaft; DP, dermal papilla; KP, keratin pearl; 
S, stromal cells. Scale bars: 25 μm.
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of Fgf7 in stromal cells and virtually no expression in tumor cells, 
while the reverse was true for p63 (Figure 5D). Thus, FGFR2 and its 
ligand FGF7 are overexpressed in different cell populations in endog-
enous SCC, suggesting activated paracrine signaling in vivo.
In the normal adult epithelium (e.g., the regenerating hair fol-
licle), FGF7 is produced by a select group of mesenchymal cells 
in the dermal papilla, resulting in restricted receptor engagement 
and limited signaling within the hair germ at the base of the fol-
licle (51). We confirmed this finding by IF staining of murine skin, 
demonstrating that only a small fraction of epithelial cells at the 
hair follicle base are exposed to and uptake FGF7, whereas the 
majority of follicle epithelial cells (marked by K14) entirely lack 
FGF7 staining (Figure 5E and Supplemental Figure 5D). In dra-
matic contrast, we observed that the ligand-producing stroma sur-
rounding the SCC cells in autochthonous tumors resulted in FGF7 
engagement at high levels in essentially all tumor cells (Figure 5E). 
Of note, membrane FGFR2 staining appeared less intense in 
tumor cells adjacent to FGF7-releasing stroma, in keeping with 
receptor internalization following ligand engagement (Supple-
mental Figure 5E). Together, these findings uncover a prominent 
role for disorganized and deregulated paracrine signaling via p63-
induced FGFR2 in the pathogenesis of endogenous SCC.
Therapeutic inhibition of FGFR signaling induces apoptosis in autochtho-
nous SCC. In order to directly validate our model of hyperactivated 
ligand-induced FGFR2 signaling in SCC, we tested the effect of 
pharmacologic FGFR2 inhibition in these tumors. Notably, as an 
established oncogenic tumor driver, FGFR2 represents a potential-
ly attractive therapeutic target in human cancer (52). We obtained 
an orally bioavailable FGFR inhibitor, AZD4547, which exhibits 
high specificity for FGFR1, -2, and -3 and low nanomolar potency 
for FGFR2 inhibition (53). We first examined FGFR2 signaling 
in FaDU HNSCC cells, which exhibit FGFR2 levels approaching 
those we observed in vivo (Supplemental Figure 6A). Cells were 
serum starved, then stimulated with FGF7 in the presence of 
increasing doses of AZD4547. Like many growth factor receptor 
tyrosine kinases, FGFR2 is reported to signal through multiple 
Figure 6
Therapeutic inhibition of ligand-activated FGFR2 signaling in SCC. (A) Inhibition of ligand-dependent FGFR2 signaling with AZD4547 extin-
guishes AKT, ERK1/2, and PLCγ phosphorylation. FaDU cells were serum starved and pretreated for 1 hour with the indicated doses of AZD4547, 
followed by a 15-minute stimulation with FGF7 ligand. (B) AZD4547 treatment blocks progression of autochthonous SCC. Mice bearing DMBA-
induced SCC tumors received daily oral AZD4547 (12.5 mg/kg, n = 7) or vehicle control (n = 6). Error bars represent SEM. P < 0.0001 as assessed 
by multiple-measures ANOVA. (C) AZD4547 treatment induces autochthonous tumor apoptosis in vivo. Tumors harvested after 17 days treatment 
as in B were assessed for cleaved caspase 3 staining by IHC. AZD4547 (n = 7), vehicle control (n = 5). *P < 0.05 as determined by Mann-Whitney 
test. (D) Quantification of Ki67-positive cells in tumors as in C. AZD4547 (n = 7), vehicle control (n = 5). P value not significant as determined by 
Student’s unpaired t test. (E) AZD4547 treatment inhibits PI3K signaling downstream of ligand-activated FGFR2 in SCC. Western blot analysis of 
autochthonous tumor lysates following 17 days of daily oral treatment with vehicle control or AZD4547 (12.5 mg/kg).
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downstream pathways, including MAPK, PI3K, and PLCγ (52). 
Low nanomolar doses of AZD4547 potently abolished FGF7-
stimulated signaling to AKT and ERK, but were less effective at 
inhibiting signaling through other reported downstream path-
ways including p38 and STAT3 (Figure 6A and Supplemental Fig-
ure 6B). Inhibition by AZD4547 was specific for FGFR2-depen-
dent signaling, as this compound did not block EGF-dependent 
signaling (Supplemental Figure 6B) and had similar effects on 
both human and murine SCC cell lines (Supplemental Figure 6C). 
These data demonstrate that AZD4547 potently and specifically 
blocks ligand-mediated FGFR2 signaling in SCC cells.
The rationale for therapeutic targeting of FGFR2 has focused 
largely on relatively uncommon tumors that exhibit activating 
somatic mutations resulting in ligand-independent signaling 
(45). Our findings suggest that FGFR2 upregulation and activat-
ed paracrine signaling in SCCs may confer pathway dependence 
in the absence of receptor mutation. To test this hypothesis, we 
established a cohort of mice bearing autochthonous DMBA-
induced SCCs and we treated these mice with either 12.5 mg/kg/d 
AZD4547 or control vehicle. This dose was well tolerated by 
mice, which exhibited no overt physiologic effects compared with 
vehicle-treated mice. Remarkably, however, AZD4547 treatment 
resulted in a virtual complete arrest of tumor progression, which 
was apparent as early as 5 days following treatment initiation and 
which was associated with a dramatic increase in progress-free sur-
vival of AZD4547-treated mice (Figure 6B and Supplemental Fig-
ure 6D). Analysis of tumors following AZD4547 treatment showed 
an increase in apoptosis as assessed by cleaved caspase 3 staining, 
while there was no discernible effect on proliferation (Figure 6, 
C and D). We then determined which of the potential FGFR2-acti-
vated signaling pathways was affected in vivo by AZD4547 treat-
ment of autochthonous tumors. We observed suppression of AKT 
phosphorylation following AZD4547 treatment, but little or no 
change in phosphorylation of ERK1/2 and PLCγ (Figure 6E). The 
dramatic suppression of Akt phosphorylation in all AZD4547-
treated compared with vehicle-treated tumors is keeping with the 
established role of the PI3K/AKT pathway in cell survival and sup-
ports an essential role for p63-induced FGFR2 in maintaining sur-
vival of autochthonous SCCs through this pathway in vivo.
Discussion
Although it has been known for several years that p63 is 
overexpressed in a large proportion of primary SCCs (18, 32, 54), 
p63 is also a marker of basal epithelial cells whose expression 
might simply reflect the lineage of origin for these tumors. Here, 
we use a sophisticated genetic model to show definitively that 
autochthonous SCCs are dependent upon high levels of endog-
enous p63. Thus, deletion of p63 induces rapid tumor regression 
without any appreciable effects on normal p63-expressing epithe-
lia (Figure 2). This finding is in stark contrast to the long latency 
required for phenotypic changes seen in normal tissues following 
in vivo excision of p63 in the epithelium (34). These results define 
SCCs as functionally “p63-addicted” and furthermore suggest that 
therapies targeting the p63 pathway may benefit from a favorable 
therapeutic window. Indeed, the lack of toxicity we observe upon 
inhibiting the p63-FGFR2 axis using AZ4547, despite its dramatic 
effect on tumors, underscores this point (Figure 6).
While our model involved deletion of all p63 isoforms, our find-
ings support a predominant role for the ΔNp63α isoform in the 
observed effects. ΔNp63α is by far the major isoform expressed 
in these tumors, and it binds directly to a conserved regulatory 
region to induce expression of FGFR2, which we show to be a cen-
tral mediator of p63-dependent tumor survival (Figure 4). In con-
trast, TAp63α is unable to modulate expression of FGFR2 (Sup-
plemental Figure 3). The particular contribution of ΔNp63α to 
squamous carcinogenesis is also supported by data presented here 
(Figure 4) and previously (10, 47) showing that ΔNp63α expres-
sion can rescue cell death induced by endogenous p63 knockdown 
and that this isoform can cooperate with oncogenic Ras to pro-
mote squamous tumorigenesis (55).
Genome-wide in vivo gene-expression profiling of tumors follow-
ing p63 excision revealed multiple p63-dependent pathways with a 
plausible role in tumor maintenance, including integrin and MAPK 
signaling, as well as direct p63-regulated genes functioning within 
these pathways, including Col17α1 and Pld1, respectively (Figure 3).
The most remarkable finding in our analysis, however, is a promi-
nent growth factor signaling program converging on FGFR2, which 
we show to be a key and direct transcriptional target of p63 in these 
tumors. The relevance of the p63-FGFR2 axis in human SCC is 
further supported by the strong correlation we observe between 
p63 and FGFR2 expression in primary human HNSCC tumors 
(Figure 4). We provide direct evidence arguing that FGFR2 mediates 
effects of p63 in SCC, showing that ectopic FGFR2 expression is 
sufficient to rescue effects of p63 knockdown and that FGFR2 res-
cues as effectively as ectopic expression of ΔNp63α itself (Figure 4). 
Additionally, we demonstrate that both FGFR2 and its ligands 
are produced at high levels in primary human and mouse tumors. 
By sorting such tumors, we demonstrated that in vivo the FGFR2 
ligand FGF7 is produced exclusively from the stroma, yielding a 
paracrine signaling axis that is not recapitulated in cultured tumor 
cells (56). Indeed, a subset of SCC cell lines adapted to grow in the 
absence of stroma is known to activate autocrine FGFR signaling, 
consistent with our finding that this signaling is an important sur-
vival mechanism in these cancers (57). Most notably, whereas the 
normal developmental pattern of FGFR2 signaling involves lim-
ited and spatially restricted ligand exposure (51), we show that in 
endogenous SCC, the FGFR2-expressing tumor cells are surround-
ed by ligand-producing stroma and as a result exhibit high levels of 
receptor-associated ligand expression (Figure 5).
Widespread activation of p63-induced FGFR2 by overexpressed 
stromal ligand, together with other stroma-associated effects (58), 
may well explain the poor prognosis associated with an abundant 
stromal component in human SCCs (21, 22). Other recent stud-
ies provide further evidence supporting our finding that stromal-
derived growth factors and FGF7 in particular contribute to SCC 
pathogenesis. Deregulated signaling in stroma cells within the der-
mis induces a field cancerization effect associated with increased 
secretion of growth factors including FGF7 from the stroma (59), 
and transgenic expression of FGF7 itself results in transforma-
tion of the epithelium (60, 61). We have also found that other 
FGFR2 ligands, including FGF1 and FGF10, are elevated in the 
tumor microenvironment, suggesting that multiple ligands could 
potentially contribute to tumor progression. Finally, in addition 
to quantitative changes in FGFR2 and FGF expression, deregulat-
ed receptor spatial orientation and stromal juxtaposition within 
depolarized, disordered epithelia are likely to play a role in height-
ened signaling through this pathway (62).
While EGFR has long been considered the most important ther-
apeutic target in SCC, the relatively modest preclinical (63, 64) and 
clinical activity of EGFR inhibitors against most SCCs, including 
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probe sets according to the manufacturer’s protocol. β-Actin mRNA 
expression in tumors served as a normalization control. Primer and probe 
sets are described in Supplemental Table 1.
IHC and IF
Assistance in processing of murine tumor samples was provided by the 
Dana-Farber/Harvard Cancer Center Specialized Histopathology Core 
Facility. Five-micron sections were cut from formalin-fixed, paraffin-
embedded tumors and stained using standard protocols. Staining for 
cleaved caspase 3 was performed using the SignalStain Cleaved Caspase-3 
(Asp175) IHC detection kit (Cell Signaling) according to the manufac-
turer’s instructions. For IF staining, murine tumors were snap-frozen in 
HistoPrep (Fisher Scientific), and 5-μM sections were cut. Samples were 
fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 
or fixed and permeabilized with methanol (K14; SMA). Nuclei were visual-
ized by staining with Hoechst 33342 dye (Invitrogen). Stains with the SMA 
antibody used the Mouse on Mouse (M.O.M.) Basic Kit (Vector Laborato-
ries) according to the manufacturer’s instructions.
Cell lines
Murine cell lines B9 (26) and SCC/80 (71) were gifts of Nabeel Bardeesy 
(Massachusetts General Hospital). Murine cell lines mSCC (25), 392-1, and 
1459A were generated from DMBA-induced tumors and established in R&G 
medium (71). Following establishment of a cell line, cells were switched to 
RPMI medium. JHU-029 (18) cells were a gift of David Sidranski (Johns Hop-
kins University, Baltimore, Maryland, USA). FaDU (72) and HaCAT (73) cells 
were a gift of James Rocco (Massachusetts General Hospital). HO1N1 (74), 
BICR-78 (75), CAL-33 (76), KYSE-30, and KYSE-150 (77) were a gift of S. 
Michael Rothenberg (Massachusetts General Hospital). Cells were main-
tained at 37°C in 5% CO2 in either RPMI or DMEM (HaCAT) supplemented 
with 10% FBS, penicillin, and streptomycin. All human cell lines were main-
tained by the MGH Center for Molecular Therapeutics cell bank and under-
went high-density SNP typing to confirm their identity.
Real-time PCR
Isolated tumor cells from autochthonous tumors were generated by disag-
gregation of primary tumors with collagenase, and cells were FACS sorted 
for viable CD31neg, CD45neg, and CD49fhi cells. For all experiments, RNA 
was extracted from whole tumors using QIAGEN RNeasy Fibrous Tissue 
Mini Kit according to the manufacturer’s instructions. QRT-PCR analy-
sis was performed using IQ SYBR Green Supermix (Bio-Rad) according to 
the manufacturer’s instructions. Primers used for QRT-PCR are listed in 
Supplemental Table 1.
Western blotting and ChIP
Protein was extracted from tumors by incubation for 1 hour at 4°C in RIPA 
buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% [w/v] 
sodium deoxycholate, 0.1% [w/v] SDS, 1% [v/v] NP-40, proteinase inhibitor 
cocktail, phosphatase inhibitor cocktail) following physical grinding. ChIP 
was performed as previously described (47). Data represent 3 to 5 indepen-
dently immunoprecipitated samples per antibody. Primer sets used can be 
found in Supplemental Table 1.
Lentiviral, retroviral production, colony forming assays, and mRNA 
QRT-PCR
Production of virus and mRNA analysis were performed as described 
previously (18). Soft agar colony-forming assays were performed by plat-
ing 3 × 104 cells per well in a 6-well plate in 0.4% agarose 72 hours follow-
ing infection with lentiviral shRNA constructs. Rescue experiments in 
Figure 4, H and I, were supplemented with 1 μM FGF7. Data represent 
HSNCC, might argue for the presence of an additional or alterna-
tive RTK-dependent pathway driving these tumors (65–67). Much 
of the attention in therapeutic targeting of FGFR-dependent 
pathways in SCC and other cancer contexts has focused on the 
relatively uncommon tumors exhibiting either amplification or 
somatic mutation of these receptors (68, 69). Our study suggests, 
however, that high levels of p63 itself are sufficient to drive FGFR2 
expression, signaling, and tumor cell dependence. In this regard, 
it is notable that the inhibition of tumor growth we observed fol-
lowing treatment of mice with AZD4547 is comparable to that 
observed using the same dose of this compound in a xenograft 
model that employed an FGFR-amplified cell line (53). Our data 
also indicate that a major impact of AZD4547 is to potently inhib-
it PI3K/AKT signaling. Consequently, this compound induced 
apoptosis when used to treat autochthonous tumors (Figure 6). 
This observation may have may have direct relevance regarding 
which patient populations may benefit from treatment with this 
drug. A small but significant fraction of HNSCCs harbor either 
mutations in the catalytic PI3K subunit PI3KCA (2, 3) or loss of 
PTEN (70) and thus may exhibit resistance to this compound 
due to constitutive PI3K activity. Given that AZD4547 and other 
potent FGFR inhibitors are now entering the clinic, it is impor-
tant to define the specific clinical context for its application. More 
broadly, our identification of a p63-driven pathway for growth 
factor signaling highlights the potential for therapeutic targeting 
of oncogenic transcriptional programs, even while targeting the 
transcription factors themselves remains a challenge.
Methods
Mice
To induce epidermal SCC tumors, 6-week-old mice were shaved and 25 mg 
DMBA (Sigma-Aldrich) dissolved in acetone was applied to the skin once per 
week. For oral SCC tumors, DMBA was applied to the inside of the oral cavity 
weekly. Tumors were measured daily, and tumor volumes were calculated using 
the following formula: tumor volume (mm3) = 4/3π × length/2 × width/2. 
In order to excise p63, mice were treated once per day with 100 mg/kg tamoxi-
fen (Sigma-Aldrich) dissolved in sunflower seed oil (Sigma-Aldrich) by 
intraperitoneal injection for 5 days. Orthotopic transplants were performed 
as described previously (25). For in vivo AZD4547 (AstraZeneca Pharmaceuti-
cals LP) treatment, tumor-bearing mice were treated daily by oral gavage with 
12.5 mg/kg AZD4547 dissolved in 1% Tween-80. Generation of p53–/–, p63L/L 
mice, and K14-CreER mice has been previously described (30, 35, 37). Analysis 
of genomic p63 excision by PCR has been previously described (34).
AZD4547 treatment of cell lines
Inhibition of signaling by AZD4547 was performed by plating cells in 
0.1% FBS for 22 hours, then serum-free medium for 1 hour. Freshly made 
AZD4547 was dissolved in DMSO and added to the medium for 1 additional 
hour. Then, 1 μM recombinant human FGF7 (Sigma-Aldrich) was added to 
cells for 15 minutes followed by lysis with RIPA buffer. IC50 values of SCC cells 
treated with AZD4547 were determined 72 hours after plating of 500 cells/
well in medium containing 10% FBS using the CellTiter-Glo Luminescent 
Cell Viability Assay (Promega) according to the manufacturer’s instructions.
Human tumor analysis
Primary HNSCC tumors used in this study have been previously described 
(25). Following pathological review, total RNA was extracted from macro-
dissected tumor-enriched portions. Quantification of mRNA from tumor 
samples was performed using the TaqMan (Applied Biosystems) primer-
Downloaded from http://www.jci.org on December 26, 2014.   http://dx.doi.org/10.1172/JCI68899
research article
3536 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 8   August 2013
(S-20; Santa Cruz Biotechnology Inc.), K14 (Covance), and α-SMA (ab7817; 
Abcam) were used.
FACS. CD45 (biotin-conjugated; eBioscience), CD31 (biotin-con-
jugated;, eBioscience), and CD49f (PE-conjugated; BD Biosciences — 
Pharmingen) were used.
Statistics
All P values were determined using the 2-tailed Student’s unpaired t test 
with the exceptions noted here. The values in Figure 2F and Figure 6C had 
non-Gaussian distributions and were analyzed using the Mann-Whitney 
test. For in vivo experiments in Figure 2D and Figure 6B, changes in tumor 
volume were analyzed using multiple-measures ANOVA. For Figure 4F, the 
Pearson product moment correlation coefficient (R2) was calculated, and the 
P value was determined from a probability table. P values for GO, KEGG, and 
Panther Pathways as analyzed using DAVID were determined using Fisher’s 
exact test. P < 0.05 was considered significant for all experiments.
Study approval
The Massachusetts General Hospital IRB approved use of tissues and clini-
cal data for this study. All human tissue studies used exclusively discarded 
material collected in the course of routine clinical care, for which our IRB 
determined that signed informed consent was not required. Housing and 
treatment for all animals was approved by the Subcommittee on Research 
Animal Care at the Massachusetts General Hospital.
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average of 3 random fields in 3 independently seeded wells, performed 
twice with similar results.
Plasmids
Retroviral pBABE (puro)-FGFR2 IIIb and pBABE (puro)-FGFR2 IIIc plasmids 
(45) were a gift of Heidi Greulich (Broad Institute, Cambridge, Massachu-
setts, USA). pLPC-ΔNp63α (WT)-FLAG, ΔNp63α (R304W)-FLAG, and 
pLPC-TAp63α (WT)-FLAG plasmids have been previously described (47).
Microarray
RNA was extracted from whole orthotopic tumors using QIAGEN RNeasy 
Fibrous Tissue Mini Kit according to the manufacturer’s instructions. 
Synthesis of cDNA, hybridization, and reading of signal intensity were 
performed by the Partners HealthCare Center for Personalized Genetic 
Medicine. RNA quality was assessed on a 2100 Bioanalyzer (Agilent), and 
total RNA was hybridized to Illumina MouseWG-6 v2 BeadChip arrays. 
Chips were scanned with Illumina BeadArray Reader to measure the signal 
intensity by the labeled target. Data were processed using the R statisti-
cal software environment, version 2.12.0 (78). Data were background cor-
rected, normalized, and underwent variance stabilizing transformations 
using the Lumi package (79). Differential gene expression was determined 
based on a moderated t test using the Limma package (80). The entire set 
of unprocessed raw data is available (GEO GSE45929).
Quantification of proliferation and apoptosis following p63 excision
For quantification of cleaved caspase 3 staining in Figure 2F, the day-6 
control group consisted of vehicle-treated p633L/L K14-CreER (n = 3) and 
tamoxifen-treated p63L/L (n = 2) mice compared with tamoxifen-treated p63L/L 
K14-CreER mice (n = 5). The day 8 control group consisted of vehicle-treated 
p63L/L K14-CreER (n = 2) and tamoxifen-treated p63L/L mice (n = 2) compared 
with tamoxifen-treated p63L/L K14-CreER mice (n = 4). For quantification of 
Ki67 staining in Figure 2G, the day-6 control group consisted of vehicle-treat-
ed p63L/L K14-CreER (n = 2) and tamoxifen-treated p63L/L (n = 1) compared with 
tamoxifen-treated p63L/L K14-CreER mice (n = 4). The day-8 control group con-
sisted of vehicle-treated p63L/L K14-CreER (n = 2) and tamoxifen-treated p63L/L 
mice (n = 1) compared with tamoxifen-treated p63L/L K14-CreER mice (n = 4).
Antibodies
Western blotting. PARP (Cell Signaling), GAPDH (FL335; Santa Cruz Bio-
technology Inc.), p53 (DO-1; Santa Cruz Biotechnology Inc.), p63 (4A4; 
Sigma-Aldrich), BCL-2 (C2; Santa Cruz Biotechnology Inc.), Erk1/2 (K-23; 
Santa Cruz Biotechnology Inc.), FLAG (M2; Sigma-Aldrich), FGFR2 
(Abcam), AKT (Cell Signaling), AKT-pSer473 (Cell Signaling), ERK1/2-
pThr202/Tyr204 (20G11; Cell Signaling), PLCγ (D9H10; Cell Signaling), 
PLCγ-pSer1248 (Cell Signaling), p38-pThr180/Tyr182 (3D7; Cell Signal-
ing), p38 (5F11; Cell Signaling), STAT3-pTyr705 (3E2; Cell Signaling), 
STAT3 (124H6; Cell Signaling), EGFR (1005, Santa Cruz Biotechnology 
Inc.), and EGFR-pTyr845 (Cell Signaling) were used.
ChIP. p63α (H-129; Santa Cruz Biotechnology Inc.) and FLAG epitope 
(M2; Sigma-Aldrich) were used.
Immunohistochemistry. Ki67 (NCL-Ki67p; Novacastra), K14 (Covance), 
and p63 (4A4; Sigma-Aldrich) were used.
IF. FGF7 (H-73 or C-19; Santa Cruz Biotechnology Inc.), FGFR2 
(ab52256; Abcam), p63 (H-129; Santa Cruz Biotechnology Inc.), Vimentin 
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